Detalles de la búsqueda
1.
XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer: a multicenter, open-label, randomized, controlled, phase 3 trial.
Signal Transduct Target Ther
; 9(1): 79, 2024 Apr 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38565886
2.
The efficacy and safety of the combination of axitinib and pembrolizumab-activated autologous DC-CIK cell immunotherapy for patients with advanced renal cell carcinoma: a phase 2 study.
Clin Transl Immunology
; 10(3): e1257, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33717483
Resultados
1 -
2
de 2
1
Próxima >
>>